Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-market Safety Reassessment of Ulinastatin for Injection

NCT02520570 is registered in ClinicalTrials.gov with Techpool Bio-Pharma Co., Ltd. as lead sponsor.

NCT NCT02520570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-market Safety Reassessment of Ulinastatin for Injection
Lead sponsor
Techpool Bio-Pharma Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2014
Completion date
August 31, 2018
Enrollment
10,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse reaction to drug